Charles River Laboratories International, INC Form 4 insider transactions

James C. Foster, Chairman, President, and CEO of Charles River Laboratories, reports a transaction involving the transfer of shares from a GRAT account to direct holdings.

Director Richard Wallman reported the disposition of Charles River Laboratories (CRL) shares through sales and a gift, according to a Form 4 filing.

William D. Barbo, Corporate Executive VP & CCO of Charles River Laboratories, transferred 965 shares of common stock to a revocable trust on November 7, 2024.

James C. Foster, Chairman, President, and CEO of Charles River Laboratories, reports a transaction involving company stock on August 12, 2024.

Joseph W. LaPlume, EVP at Charles River Laboratories, sold 1,780 shares of common stock on August 8, 2024, at a price of $199.36 per share.

James C. Foster, Chairman, President, and CEO of Charles River Laboratories, reported the sale of 25,000 shares of common stock on August 1, 2024.

Joseph W. LaPlume, EVP at Charles River Laboratories, reports a gift of 311 common stock shares.

Shannon M. Parisotto, a CEVP at Charles River Laboratories, reported the acquisition of restricted stock units and stock options, along with holdings through Karpathos Investments LLC.

Victoria Creamer, EVP & Chief People Officer at Charles River Laboratories, reports the acquisition of common stock and stock options.

Birgit Girshick, Corporate Executive VP & COO of Charles River Laboratories, reports acquisition of stock and options.

James C. Foster, Chairman, President, and CEO of Charles River Laboratories, reports acquisition of stock options.

Flavia Pease, Corporate Executive VP & CFO of Charles River Laboratories, reports acquiring shares through restricted stock units and stock options, while also disposing of shares.

Michael Gunnar Knell, CSVP & Chief Accounting Officer of Charles River Laboratories, reports the acquisition of stock options and restricted stock units.

Joseph W. LaPlume, EVP at Charles River Laboratories, reports acquisition of stock and options in the company.

Joseph W. LaPlume, EVP at Charles River Laboratories, reports disposition of shares to cover tax obligations.

Shannon M. Parisotto, CEVP at Charles River Laboratories, reported the disposition of 110 shares of common stock to cover tax obligations and indirectly owns 26,529 shares through Karpathos Investments LLC.

Corporate Executive VP & CCO William D. Barbo reported a transaction involving Charles River Laboratories stock on May 29, 2024.

Victoria Creamer, EVP & Chief People Officer at Charles River Laboratories, filed an amendment to a previous Form 4, reporting the disposal of shares to cover tax obligations.

Flavia Pease, Corporate Executive VP & CFO of Charles River Laboratories, reports the disposal of common stock to cover tax obligations.

Corporate Executive VP & CCO of Charles River Laboratories, William D. Barbo, filed an amendment to a previous Form 4, reporting the disposal of common stock to cover tax obligations.

James C. Foster, Chairman, President, and CEO of Charles River Laboratories, reports a transaction involving common stock on May 29, 2024.

Charles River Laboratories' CSVP & Chief Accounting Officer, Michael Gunnar Knell, reports disposition of shares to cover tax obligations.

Victoria L. Creamer, EVP & Chief People Officer at Charles River Laboratories, reported the disposal of 190 shares of common stock on May 29, 2024, to cover tax obligations.

Birgit Girshick, Corporate Executive VP & COO of Charles River Laboratories, reported disposing of 216 shares of common stock on May 29, 2024, to cover tax obligations.

Flavia Pease, Corporate Executive VP & CFO of Charles River Laboratories, reported disposing of common stock to cover tax obligations.

Michael Gunnar Knell, CSVP & Chief Accounting Officer of Charles River Laboratories, disposed of shares to cover tax obligations arising from vesting of restricted stock units.

Michael Gunnar Knell, CSVP & Chief Accounting Officer of Charles River Laboratories, reports the acquisition and disposal of common stock on March 8, 2024, according to a Form 4/A filing.

Victoria L. Creamer, EVP & Chief People Officer at Charles River Laboratories, reported the disposal of common stock to cover tax obligations arising from equity awards.

William D. Barbo, Corporate Executive VP & CCO of Charles River Laboratories, reported disposing of shares to cover tax obligations arising from vesting of restricted stock.

Shannon M. Parisotto, a CEVP at Charles River Laboratories, reported disposing of common stock to cover tax obligations arising from equity awards.